Skip Navigation
Alvotech

Better Access. Better Lives.

We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.

  • AVT02

    Biosimilar candidate
    High-concentration, low-volume adalimumab
    Reference biologic
    HUMIRA®
    Therapeutic area
    Immunology

    Approved by

    • EU/EEA
    • Canada
    • UK
    • Egypt
    • Saudi Arabia
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT04

    Biosimilar candidate
    ustekinumab
    Reference biologic
    STELARA®
    Therapeutic area
    Immunology

    Approved by

    • Japan
    • Canada
    • EU/EEA
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT23*

    Biosimilar candidate
    omalizumab
    Reference biologic
    XOLAIR®
    Therapeutic area
    Respiratory
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT03

    Biosimilar candidate
    denosumab
    Reference biologic
    PROLIA®/XGEVA®
    Therapeutic area
    Bone Disease
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT05

    Biosimilar candidate
    golimumab
    Reference biologic
    SIMPONI®/SIMPONI ARIA®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT06

    Biosimilar candidate
    aflibercept
    Reference biologic
    EYLEA®
    Therapeutic area
    Ophthalmology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT16

    Biosimilar candidate
    vedolizumab
    Reference biologic
    ENTYVIO®
    Therapeutic area
    Immunology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT33

    Biosimilar candidate
    pembrolizumab
    Reference biologic
    KEYTRUDA®
    Therapeutic area
    Oncology
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT19

    Biosimilar candidate
    Undisclosed
    Reference biologic
    Undisclosed
    Therapeutic area
    Undisclosed
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT28

    Biosimilar candidate
    Undisclosed
    Reference biologic
    Undisclosed
    Therapeutic area
    Undisclosed
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch
  • AVT41

    Biosimilar candidate
    Undisclosed
    Reference biologic
    Undisclosed
    Therapeutic area
    Undisclosed
    • Early Phase
    • Pre-clinical
    • Clinical Trials
    • Filing
    • Approval
    • Launch

HUMIRA is a registered trademark of AbbVie Inc.
STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Johnson & Johnson Inc.
XOLAIR is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals Inc.
ENTYVIO is a registered trademark of Millenium Pharmaceuticals Inc.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp.